Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Prediction Markets
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
  • WIIM
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

FDA

FDA

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • FDA
  • News

Heron Therapeutics Publishes Clinical Trial Titled ‘HTX-011 in Spinal Surgery’ To ClinicalTrials.Gov

By Benzinga Newsdesk
Today, 8:25 AM
https://clinicaltrials.gov/ct2/show/NCT04911062

HRTX

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

Bristol Myers’ Opdivo-Yervoy Combo Approved In Europe, Canada For Malignant Pleural Mesothelioma

By Vandana Singh
Today, 8:25 AM
The regulatory authorities in Europe and Canada have approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment…

BMY

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Penny Stocks
  • Small Cap

Mereo’s Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome

By Vandana Singh
Today, 8:25 AM
Mereo BioPharma Group plc (NASDAQ:MREO) has announced data from an interim analysis of an investigator-initiated study of alvelestat, in patients with…

MREO

Read More
1 minute read
  • Contracts
  • FDA
  • General
  • News
  • Politics

Kuwait Approved Sotrovimab Treatment For COVID-19

By Benzinga Newsdesk
Today, 8:25 AM
-Reuters Citing State Media

GSK

Read More
5 minute read
  • FDA
  • News

Lixte Biotechnology, City Of Hope Enroll First Patient In Phase 1b Trial Of Lead Compound LB-100 For Treatment Of Small Cell Lung Cancer

By Benzinga Newsdesk
Today, 8:25 AM
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer Extensive preclinical data shows LB-100 increases the effectiveness

LIXT

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Small Cap

Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials

By Vandana Singh
Today, 8:25 AM
The FDA has signed off Seres Therapeutics Inc’s (NASDAQ:MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial.…

MCRB

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Small Cap

BeyondSpring’s Plinabulin US Application for Chemo-Induced Neutropenia Under Review

By Vandana Singh
Today, 8:25 AM
The FDA has accepted for review BeyondSpring Inc’s (NASDAQ:BYSI) marketing application seeking approval for the use of plinabulin in combination with…

BYSI

Read More
1 minute read
  • FDA
  • General
  • News
  • Politics

White House Official Says CDC Closely Tracking Avian Flu Case In China

By Benzinga Newsdesk
Today, 8:25 AM
-Bloomberg

FXI

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Penny Stocks
  • Small Cap

Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia

By Vandana Singh
Today, 8:25 AM
Akebia Therapeutics Inc (NASDAQ:AKBA) and its collaborator Otsuka Holdings (OTC:OTSKY) have announced that the FDA has accepted to review vadadustat’s marketing application for…

AKBA

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

Sanofi Stops Venglustat Development In Rare Genetic Kidney Disorder

By Vandana Singh
Today, 8:25 AM
Sanofi SA (NASDAQ:SNY) has halted the clinical program of venglustat in autosomal dominant polycystic kidney disease (ADPKD). Although the safety profile…

SNY

Posts navigation

Previous 1 … 567 568 569 … 571 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service